sbp-7455
CAS No. 1884222-74-5
sbp-7455 ( —— )
Catalog No. M23859 CAS No. 1884222-74-5
SBP-7455 potently inhibited ULK1/2 enzymatic activity in vitro and in cells, reduced the viability of TNBC cells and had oral bioavailability in mice.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 109 | In Stock |
|
10MG | 182 | In Stock |
|
25MG | 328 | In Stock |
|
50MG | 535 | In Stock |
|
100MG | 671 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product Namesbp-7455
-
NoteResearch use only, not for human use.
-
Brief DescriptionSBP-7455 potently inhibited ULK1/2 enzymatic activity in vitro and in cells, reduced the viability of TNBC cells and had oral bioavailability in mice.
-
DescriptionSBP-7455 potently inhibited ULK1/2 enzymatic activity in vitro and in cells, reduced the viability of TNBC cells and had oral bioavailability in mice.
-
Synonyms——
-
PathwayAutophagy
-
TargetAutophagy
-
RecptorULK1;ULK2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1884222-74-5
-
Formula Weight354.3
-
Molecular FormulaC16H17F3N4O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:120mg/mL (338.67 mM)
-
SMILESCOC1=C(OC)C=CC(NC2=NC(NC3CC3)=C(C(F)(F)F)C=N2)=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ren H, Bakas NA, Vamos M, et al. Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer. J Med Chem. 2020;63(23):14609-14625. doi:10.1021/acs.jmedchem.0c00873
molnova catalog
related products
-
Lys05
Lys05 (Lys01 trihydrochloride, PS-1001)is the water-soluble salt of Lys01, is a 10-fold more potent lysosomal autophagy inhibitor than hydroxychloroquine (HCQ); shows IC50 values of 3.6, 3.8, 6 and 7.9 uM for 1205Lu, c8161, LN229 and HT-29 cell line in the MTT assay.
-
Talarozole
Talarozole is an oral systemic all-trans retinoic acid metabolism blocking agent (RAMBA). Talarozole inhibits both CYP26A1 and CYP26B1 with IC50s of 5.4 and 0.46 nM respectively.Talarozole for the treatment of acne psoriasis and other keratinization disorders.
-
Cysteamine
An agent for the treatment of nephropathic cystinosis and an antioxidant.